176967-80-9

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Bromo-8-nitroquinoline is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Synthesis:
5-Bromo-8-nitroquinoline is utilized as a precursor in the production of agrochemicals, playing a crucial role in the creation of compounds that can enhance crop protection and yield.
Used in Organic Material Preparation:
5-Bromo-8-nitroquinoline is employed as a component in the preparation of novel organic materials, leveraging its chemical properties to contribute to the advancement of material science.
Used in Fluorescence and Luminescence Studies:
5-Bromo-8-nitroquinoline is used as a research tool in fluorescence and luminescence studies due to its strong absorption in the UV-visible region, aiding in the understanding of light-matter interactions and the development of new imaging techniques.
Used in Chemical Compound Synthesis:
5-Bromo-8-nitroquinoline is used as a versatile precursor for the synthesis of various other chemical compounds, expanding its applications across a wide range of industries.

InChI:InChI=1/C9H5BrN2O2/c10-7-3-4-8(12(13)14)9-6(7)2-1-5-11-9/h1-5H

Upstream product

• 4964-71-0 5-bromoquinoline 
• 50358-42-4 6-amino-5-bromoquinoline 
• 580-15-4 6-aminoquinoline 
• 591-19-5 m-Bromoaniline 

Downstream Products

• 53472-18-7 5-bromo-8-aminoquinoline 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 
• 56017-33-5 8-nitro-5-phenylsulfanyl-quinoline 
• 56017-36-8 5-(phenylthio)quinolin-8-amine 

Relevant academic research and scientific papers

Toll-like receptor-7 small molecule inhibitor and preparation method thereof

The invention belongs to the field of chemical small molecules, and particularly relates to a Toll-like receptor-7 small molecule inhibitor. The invention provides the Toll-like receptor-7 small molecule inhibitor, which takes a co-inhibitor of TLR7 and TLR8 obtained by screening as a research object, realizes selective regulation and control of TLR7 and TLR8 through the research on the structureoptimization and structure-activity relationship (SAR) of a parent compound, and further develops a high-efficiency, non-toxic and specific small molecule inhibitor with certain selectivity on TLR 7.The TLR7 small molecule inhibitor has a certain effect and potential medicinal value in autoimmune diseases (systemic lupus erythematosus).

Metal-Binding Pharmacophore Library Yields the Discovery of a Glyoxalase 1 Inhibitor

Anxiety and depression are common, highly comorbid psychiatric diseases that account for a large proportion of worldwide medical disability. Glyoxalase 1 (GLO1) has been identified as a possible target for the treatment of anxiety and depression. GLO1 is a Zn2+-dependent enzyme that isomerizes a hemithioacetal, formed from glutathione and methylglyoxal, to a lactic acid thioester. To develop active inhibitors of GLO1, fragment-based drug discovery was used to identify fragments that could serve as core scaffolds for lead development. After screening a focused library of metal-binding pharmacophores, 8-(methylsulfonylamino)quinoline (8-MSQ) was identified as a hit. Through computational modeling and synthetic elaboration, a potent GLO1 inhibitor was developed with a novel sulfonamide core pharmacophore. A lead compound was demonstrated to penetrate the blood-brain barrier, elevate levels of methylglyoxal in the brain, and reduce depression-like behavior in mice. These findings provide the basis for GLO1 inhibitors to treat depression and related psychiatric illnesses.

Novel Sulfonaminoquinoline Hepcidin Antagonists

The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.